Key result
T2DM linked to ~49% higher D-dimer levels in AF, indicating increased coagulation activity.
Why the study?
Does the presence of type 2 diabetes mellitus increase coagulation activity, as measured by D-dimer levels, in adult patients with non-valvular atrial fibrillation?
Observational (n=300)
No
Does the presence of type 2 diabetes mellitus increase coagulation activity, as measured by D-dimer levels, in adult patients with non-valvular atrial fibrillation?
In patients with non-valvular atrial fibrillation, comorbid type 2 diabetes is independently associated with a hypercoagulable state as evidenced by elevated D-dimer levels.
Answers are grounded in this paper and cite their sources.
T2DM may mark heightened coagulation in AF; extends observational data but leaves practice change open pending prospective trials.
Background: Atrial Fibrillation (AF) is associated with a prothrombotic state and increased risk of ischemic stroke. Type 2 diabetes mellitus (T2DM) is a major cardiometabolic comorbidity in AF and independently increases thromboembolic risk. D-dimer is a well-established biomarker of coagulation activation and fibrin turnover, but the specific contribution of T2DM to D-dimer levels in AF remains insufficiently characterized in real-world cohorts. Methods: We conducted a retrospective, observational, single-center study including 300 adult patients with non-valvular AF evaluated at a tertiary university hospital. Patients were stratified according to the presence of T2DM (150 with T2DM and 150 without diabetes). Plasma D-dimer levels were compared between groups and analyzed across clinically relevant thresholds and CHA2DS2-VASc categories. Multivariable linear and logistic regression models were used to assess the independent association between T2DM and D-dimer levels after adjustment for demographic factors, comorbidities, renal function, prior stroke, CHA2DS2-VASc score components, and oral anticoagulation. Results: Patients with T2DM exhibited significantly higher D-dimer levels than non-diabetic patients (median 0.94 vs. 0.63 µg/mL FEU, p < 0.001). T2DM was independently associated with higher log-transformed D-dimer levels (adjusted β = 0.19, p < 0.001) and with increased odds of elevated D-dimer above both 0.5 µg/mL and 1.0 µg/mL thresholds. Across all CHA2DS2-VASc categories, patients with T2DM consistently showed higher D-dimer concentrations. Findings remained robust in sensitivity analyses restricted to anticoagulated patients. Conclusions: In patients with atrial fibrillation, type 2 diabetes mellitus is associated with increased coagulation activity as reflected by higher D-dimer levels, independent of clinical thromboembolic risk. These results support the concept of a diabetes-associated hypercoagulable AF phenotype and highlight the potential role of coagulation biomarkers in refining risk stratification.
No takes yet. Share an insight, caveat, or question.
Ciubotaru et al. (2026) conducted an observational in Non-valvular atrial fibrillation (n=300). Type 2 diabetes mellitus vs. No diabetes was evaluated on Plasma D-dimer levels (adjusted β 0.19, p=< 0.001). In patients with atrial fibrillation, type 2 diabetes mellitus was associated with higher median D-dimer levels compared to non-diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: